Introduction
Very low density lipoproteins (VLDL)' isolated from plasmas of patients with hypertriglyceridemia seem to be taken up by normal cultured human fibroblasts much more readily than Received for publication 2 September 1983 and in revised form 15 October 1984. 1 . Abbreviations used in this paper: apo B, apolipoprotein B; apo E, apolipoprotein E; Fab, antigen-binding fragment; HTG, hypertriglyceridemic; TMU, tetramethylurea. VLDL isolated from normal plasma (1, 2) . Density gradient ultracentrifugation can be used to subfractionate VLDL (3, 4) , and it seems that differences between the cell reactivities of normal and hypertriglyceridemic (HTG) VLDL are most readily apparent when the largest particles, Sf > 100, or VLDLI fractions are compared (5) . The cellular uptake of the VLDLI fraction, which contains both apo B and apo E (6) (7) (8) , is mediated by the same apo B,E receptor on fibroblasts (9) (10) (11) (12) that recognizes low density lipoprotein (LDL) (13) , which contains only apo B (13) (14) (15) . Therefore, it was of great interest when Gianturco et al. ( 16) recently reported that the recognition of HTG-VLDL, by fibroblasts occurred via apo E rather than apo B. Gianturco et al. (16) reached this conclusion by showing that thrombin digestion of VLDL, abolished its cellular recognition. Concomitantly, VLDL,-apo E was cleaved into two major 22,000-and 12,000-mol wt peptides. Similar treatment of LDL had no effect on its recognition by cells. Furthermore, addition of intact apo E to thrombin-treated VLDL, restored its capacity to interact with cells, and addition of apo E to VLDLI isolated from normolipidemic subjects increased its recognition by cells.
We also have been interested in the interaction of apo Bcontaining lipoproteins with cultured cells (17) (18) (19) , and have developed mouse monoclonal anti-human LDL antibodies as probes of lipoprotein-apo B structure and as inhibitors of lipoprotein-cell interactions. Two monoclonal IgG antibodies, 2a and 2b, have been reported with the following characteristics: a) both antibodies 2a and 2b and the antigen-binding fragment (Fab) of antibody 2a effectively block the apo B,E receptormediated binding and degradation of '25I-LDL in cultured normal human fibroblasts, while other anti-apo B antibodies do not inhibit cellular binding (18) ; b) chemical modification ofthe lysyl and arginsyl residues of LDL destroys the recognition of LDL by antibodies 2a and 2b, and also by fibroblasts (18) ; c) limited proteolysis of LDL destroys the immunoreactivities of the LDL cores vis-a-vis several monoclonal antibodies, but the abilities of the LDL cores to bind to antibodies 2a and 2b and to fibroblast LDL receptors are preserved (19) ; and d) LDL of other species of animals bind to antibodies 2a and 2b, but not to other antibodies (20) . From these findings, we conclude that antibodies 2a and 2b define epitopes on apo B that are closely related to the cell recognition domains on apo B. Apo E either in its delipidated form or reconstituted in dimyristoylphosphatidylcholine vesicles does not react with antibodies 2a and 2b (G. Schonfeld, unpublished observations). Anti-human apo E monoclonal antibodies have also been developed in this laboratory. Two of these antibodies, 1506 A 1.4 and 1907 F6.4, were used in the present study in an attempt to block apo E-mediated cell binding.
In the experiments to be reported, the apo B and apo E antibodies were used to inhibit the cell recognition of VLDL subfractions and LDL, to assess the roles of apo B and apo E 
Methods
Lipoprotein donors. Lipoproteins of six subjects with hypertriglyceridemia and six normal controls were studied. Clinical characteristics are given in Table I . Lipoprotein lipid values are representative of those obtained for each subject at diagnosis. Patients were not taking medications and none had visible chylomicronemia.
Isolation of lipoproteins. Blood collected in 0.1% EDTA was obtained from subjects after 12-14 h of fasting. After separation of cells by centrifugation, 10 AM phenylmethylsulfonyl fluoride, 50 mg/i chloramphenicol and 50 mg/l gentamycin were added to the plasma (16, 21) . VLDL was immediately isolated by ultracentrifugation at d = 1.006. LDL was isolated between the densities of 1.019 and 1.050 (22) . Two ultracentrifugations were carried out at each density. VLDL density subfractions were isolated from VLDL that had been centrifuged only once, by zonal ultracentrifugation using a linear density gradient of 1.00-1.15 g/ml (17, 23) . The fastest floating fraction (5120-400) was designated fraction VLDL,; the S60-120 fraction, VLDL2; and Sf20-60 fraction, VLDL3. On occasion, VLDL fractions were obtained by ultracentrifugation in a salt gradient formed in an SW40 swinging bucket rotor (3) . After dialysis against 0.15 M sodium chloride and I mM EDTA (pH 8.2), the lipoproteins were concentrated by dry analysis (Aquacide IIA; Calbiochem-Behring Corp., American Hoechst Corp., San Diego, CA), dialyzed against EDTA-saline, filtered through 0.45-,um filters (Acrodisc; Gelman Sciences, Inc., Ann Arbor, MI), and stored in EDTA-saline containing the above mentioned concentrations of antibacterial agents at 4°C.
The purities of the isolated VLDL and LDL preparations were assessed by 3-10% or 3-20% sodium dodecyl sulfate polyacrylamide gradient gel electrophoresis of the individual samples (24) . VLDL apo B/E ratios were calculated from these gels in some experiments. In LDL, three bands corresponding to apo B-100, B-74, and B-26 (8) were found by Coomassie Blue staining, but none of the LDL samples contained detectable amounts of B-48, serum albumin, or non-apo B apolipoproteins (21) . The HTG-VLDL preparations used in the studies reported here contained apo B-100, trace amounts of apo B48 and B-26 ( Fig. 1) , apo E, and apolipoprotein C. The apo B contents of the VLDL subfractions and LDL were determined by tetramethylurea (TMU) precipitation (8) . Apo E contents were quantitated by radioimmunoassay (RIA) after pretreatment of the VLDL with 6 M urea (25) . Total protein contents were measured by modifications of the method of Lowry et al. (26, 27) .
Preparation of purified antibodies and Fab fragments. Affinity purified human apo B monoclonal antibodies and Fab fragments were prepared as previously described (18) . The purity of the Fab fragments was checked by sodium dodecyl sulfate gel electrophoresis in the presence of 1% 2-mercaptoethanol (1000C for 2 min), which yielded two bands of 26,500 and 25,000 apparent molecular weight. The antiapo B antibodies used in the present study are 464BIB3 (2a) and 464B1B6 (2b), which inhibit binding of LDL to receptors and also define closely related but not identical epitopes 2a and 2b. Antibodies 457C4D, (la), and 467D3D5 (6), which do not inhibit LDL binding and define two other spatially independent epitopes called la and 6, were also used as controls.
Monoclonal antibodies were raised against human apo E. The details of their preparation are described elsewhere (Krul, E. S., M. J. Tikkanen, and G. Schonfeld, manuscript in preparation). The antiapo E monoclonal IgG fraction of ascitic fluid was purified by chromatography on either DEAE Affi-Gel Blue (Bio-Rad Laboratories, Richmond, CA) (28) or Protein-A Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) (29) . The apo E antibodies used in the present study are 1506 A1. 4, 1907 F6.4 , and 1363 C3Al0, and are all of the IgG, subclass. Six IgM antibodies were also used (827, 1365, and 1366 series).
Polyclonal anti-human apo E antiserum (R224-3) was produced in rabbits (25) and the IgG was purified by ion exchange chromatography on cellulose (DE52; Whatman Chemical Separation, Inc., Clifton, NJ). Nonimmune immunoglobulins were isolated from nonimmunized mouse serum by (NH4)2SO4 precipitation (20-40% of saturation), followed by chromatography on Protein-A Sepharose (29) .
"25-labeling of lipoproteins and antibodies. VLDL fractions and LDL used in the cell assays were '251I-labeled to a specific activity of -100 cpm/ng using the iodine monochloride method (30, 31) . >90% of the 125I-lipoproteins were precipitable by 10% TCA. The lipid solvent (chloroform/methanol, 2:1 vol/vol) extractable counts for '251I-VLDL were 9-17%, and for '251-LDL, were 7-9%. Inhibition by anti-apo B antibodies and Fab fragments of the interaction of VLDL subfractions and LDL with cultured human fibroblasts. To ascertain the antibody dosage required to obtain maximum inhibition, increasing amounts of antibody 2b were added to dishes containing 25 ,ug/ml of each VLDL subfraction and of LDL (Fig. 2) . Maximum inhibition was achieved at 10 ,ug/ml of antibody for all VLDL and LDL fractions. Antibody 2b inhibited LDL-stimulated cholesterol esterification by -90% (18) . VLDLI-stimulated esterification was not inhibited, while stimulation by VLDL3 was inhibited by 70%. In agreement with the above, when in other experiments 10-25 ,ug/ml of lipoprotein proteins were incubated with 25 and 50 pg/ml of antibodies 2a, 2b, or Fab fragments of 2a (to ensure saturation of antibody binding sites on the lipoprotein particles), the binding and degradation by normal human fibroblasts of 1251I-VLDLI, 1251I-VLDL2, '251I-VLDL3, and 251I-LDL were inhibited least for 1251I-VLDL1 and most for 1251I-LDL (Table II and Fig. 3 ). The same antibodies and Fab fragments also inhibited cholesterol esterification dependent on VLDL3 by 35-73%, on VLDL2 by <5-32%, and on VLDL1 by <5-12% (Table II) Incubations of fibroblasts in the presence of normolipidemic lipoproteins and antibodies were also carried out (Fig. 4 A-C (1). Inhibiting effects of antibodies on the lipoprotein-dependent cholesterol esterification were difficult to discern in view of the low rates of stimulated esterification. However, where stimulation of esterification was appreciable (Fig. 4 B) , antibody 2b demonstrated inhibition similar to that observed for HTG-
VLDL3.
Inhibition by homologous VLDL subftractions and by LDL of the cellular interactions of I251-VLDL subfractions and of '2SI-LDL. Each VLDL subfraction was able to inhibit the cellular degradation of its labeled homologue (Table III) . Inhibition in the presence of 20-fold excesses of nonlabeled VLDL subfraction ranged from 40 to 64% (Table III) VLDLI degradation is probably due to an exchange of radiolabeled apoproteins between the tracer and cold VLDLI (16) . As the percentage of TMU-soluble apoproteins decreases, i.e., VLDL2 -VLDL3 (22), the potential for exchange would diminish and could account for the increasing inhibiting effect of unlabeled VLDL2 and VLDL3 on tracer degradation.
In contrast with unlabeled VLDL used as inhibitors, 20-fold excess of unlabeled LDL inhibited 125I-VLDL by <5%, 1251-VLDL2 by only 9-27%, and '25I-VLDL3 by only 24-47%, while LDL inhibited the degradation of 1251I-LDL by -90%.
Thus, the patterns of inhibition produced by antibodies 2a, 2b, and Fab fragments were similar to the patterns produced by excess unlabeled LDL.
To document that the VLDL cell interactions were occurring at the cellular LDL (apo B,E)-receptor, 125I-LDLs were incubated at 4°C in the presence of competing nonlabeled LDL and VLDL (Table IV) . VLDL and LDL were equally were loaded in 3% BSA-PBS buffer, pH 7.4, onto an immunoaffinity column containing monoclonal anti LDL antibody 2b coupled to Sepharose 4B.
5 were iodinated and subjected to affinity chromatography on a column containing antibody 2b (Table V) . 23% of VLDL1, 53% of VLDL3, and 34% of the whole VLDL (d < 1.006) were bound. In control experiments, iodinated HDL was passed through the same column, and the 1251-VLDL fractions and '25I-LDL were also passed through a column containing no antibodies. Virtually all of 1251I-LDL, but none of '25I-HDL, were bound to the antibody-containing column. < 1.0% of any of the lipoproteins was retained on the control column. To ascertain that there was no selective retention of apo B on the column, the proportion of TMU-precipitable counts in the starting whole 125I-VLDL and in nonbound 125I-VLDL fractions were compared. They were found to be indistinguishable (50 and 53%, respectively), suggesting that the apo B and non-apo B proteins of VLDL were not dissociated on the column. The retention of VLDL fractions by the column was similar to the rank order of competition potencies of the fractions in the competitive immunoassays. Also, the inhibition by antibody 2b of VLDL-dependent cholesterol esterification was compatible with the affinity column data (Table II) Suggest that the expression of the 2a and 2b epitopes on VLDL is inversely related to VLDL size. Inhibition by anti-apo E antibodies of the interaction of VLDL and LDL fractions with cultured human fibroblasts. Since a significant proportion of HTG-VLDL1 and VLDL2 cellular uptake could not be inhibited by anti-apo B antibodies 2a or 2b, it followed that other apolipoproteins on the surface of these lipoproteins could be responsible for binding to cells. Therefore, antibodies directed against apo E were tested for their abilities to block VLDL-cell interactions (Figs. 5 and 6 ).
Polyclonal anti-apo E antiserum (R224-3) inhibited binding (not shown) and degradation of VLDL, by -25% (Fig. 6) , and VLDL1-dependent cholesterol esterification by -45% (Fig. 5) . On the other hand, VLDL3 was poorly inhibited if at all under the same conditions. Two anti-apo E monoclonal antibodies were even more effective inhibitors of VLDL,-cell interactions (Figs. 5 and 6 , B and C). These antibodies did not inhibit VLDL3. Differences in apo E content of the VLDL fractions cannot account for the difference in antibody inhibition ( Fig. 6 ), since VLDL3 generally has less apo E than VLDLI and therefore antibody was clearly in excess. A third monoclonal anti-apo E antibody, 1363 C3A10, did not prevent cellular uptake and processing of either normolipidemic (Fig.  4 D) or HTG-VLDL subfractions (Figs. 5 D and 6 D) . Six other monoclonal IgM anti-apo E antibodies also were equally ineffective in inhibiting VLDL uptake (not shown).
Interestingly, in several cases the anti-apo E antibodies seemed to enhance the cellular processing of the HTG-VLDL3 (Figs. 5 and 6 ). This effect may be due to a conformational change in the lipoprotein structure induced by antibodybinding to a determinant distant from the cellular recognition site (cooperativity) such that cellular uptake is enhanced. Another explanation of the enhanced uptake is the possible interaction of the antibody-VLDL3 immune complex with a purported Fc receptor on human fibroblast (37) . As the Fc receptor binds aggregated IgG or immune complexes preferentially over monomeric IgG, this may explain the increased stimulation of VLDL3 uptake at higher antibody/antigen ratios (Figs. 5 and 6 ). However, these experimental results do not distinguish whether the relevant domain is buried or weakly reactive for other reasons. Another possibility for the gradual changeover from apo E to apo B may be simply that there are more molecules of apo E per particle on large than on small VLDL, and virtually none on LDL. This idea is supported by the observation that apo E contents of VLDLI tend to be higher than those for VLDL3 (Krul, E. S., M. J. Tikkanen, and G. Schonfeld, manuscript in preparation) (Fig. 6) , and by the direct relationship between binding of phospholipid vesicles to fibroblasts and the amounts of functional apo E associated with the vesicles (10, 11) . The effective interactions of HTG-VLDL with cells and the lack of such interactions by normal VLDL, also may be due to the presence of greater amounts of apo E on the former (50) (51) (52) . A third alternative is that the conformation of apo E in VLDLI favors cellular interaction but apo E conformations may change during lipolysis and catabolism of VLDL in an unfavorable direction. These three alternatives are not mutually exclusive, and one or more of them may be operating at the same time, but more work is needed to ascertain which are operative and to what extent.
